← FDA DRUG APPROVALS

FDA NDA · NDA050619

MYCOSTATIN

Sponsor: DELCOR ASSET CORP

APPLICATION
NDA050619
TYPE
NDA
ORIGINAL APPROVAL
1987-04-09
LATEST ACTION
2003-04-30
ROUTE
ORAL
DOSAGE FORM
PASTILLE
MARKETING STATUS
Discontinued

Products

MYCOSTATINDiscontinued
NYSTATIN 200,000 UNITS · PASTILLE · ORAL

Approval history

2003-04-30Labeling · Supplement 4 · standardLetterAP
1999-02-11Manufacturing (CMC) · Supplement 3 · standardAP
1998-11-13Labeling · Supplement 2 · standardAP
1994-04-26Labeling · Supplement 1 · standardAP
1987-04-09Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →